Advances in biomimetic regeneration of elastic matrix structures

Drug Delivery and Translational Research

Volumn 2, Issue 5, 2012, Pages 323-350

  Sivaraman, Balakrishnan ^a   Bashur, Chris A ^a   Ramamurthi, Anand ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Elastic fibers; Elastin; Extracellular matrix; Induced elastogenesis; Matrix assembly; Regenerative tissue repair

Indexed keywords

DOXYCYCLINE; ELASTIN; NANOCARRIER; TISSUE SCAFFOLD; TROPOELASTIN;

BIOMIMETICS; BLADDER; CELL REGENERATION; CELLULAR DISTRIBUTION; CONNECTIVE TISSUE; DEGRANULATION; ELASTIC FIBER; ELASTIC TISSUE; EXTRACELLULAR MATRIX; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DEGRADATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REGENERATIVE MEDICINE; REVIEW; SKIN; SOFT TISSUE; TISSUE ENGINEERING; VOCAL CORD;

EID: 84873283727     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-012-0070-6     Document Type: Review

References (398)

1. Mason C, Dunnill P. A brief definition of regenerative medicine. Regen Med. 2008;3(1):1-5.
2. Greenwood HL, Thorsteinsdottir H, Perry G, Renihan J, Singer PA, Daar AS. Regenerative medicine: new opportunities for developing countries. Int J Biotechnol. 2006;8(1-2):60-77.
3. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J R Soc Interface. 2011;8(55):153-170.
4. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat Biotech. 2005;23(1):47-55.
5. Davis ME, Hsieh PCH, Grodzinsky AJ, Lee RT. Custom design of the cardiac microenvironment with biomaterials. Circ Res. 2005;97(1):8-15.
6. DeWitt A, Iida T, Lam HY, Hill V, Wiley HS, Lauffenburger DA. Affinity regulates spatial range of EGF receptor autocrine ligand binding. Dev Biol. 2002;250(2):305-316.
7. Fraidenraich D, Stillwell E, Romero E, Wilkes D, Manova K, Basson CT, et al. Rescue of cardiac defects in Id knockout embryos by injection of embryonic stem cells. Science. 2004;306(5694):247-252.
8. Dai JP, Losy F, Guinault AM, Pages C, Anegon I, Desgranges P, et al. Overexpression of transforming growth factor-beta 1 stabilizes already-formed aortic aneurysms-a first approach to induction of functional healing by endovascular gene therapy. Circulation. 2005;112(7):1008-1015.
9. Kothapalli CR, Gacchina CE, Ramamurthi A. Utility of hyaluronan oligomers and transforming growth factor-beta1 factors for elastic matrix regeneration by aneurysmal rat aortic smooth muscle cells. Tissue Eng. 2009;15(11):3247-3260.
10. Kothapalli CR, Taylor PM, Smolenski RT, Yacoub MH, Ramamurthi A. Transforming growth factor beta 1 and hyaluronan oligomers synergistically enhance elastin matrix regeneration by vascular smooth muscle cells. Tissue Eng. 2009;15(3):501-511.
11. Losy F, Dai JP, Pages C, Ginat M, Muscatelli-Groux B, Guinault AM, et al. Paracrine secretion of transforming growth factor-beta (1) in aneurysm healing and stabilization with endovascular smooth muscle cell therapy. J Vasc Surg. 2003;37(6):1301-1309.
12. Sales VL, Engelmayr GC, Mettler BA, Johnson JA, Sacks MS, Mayer JE. Transforming growth factor-beta 1 modulates extra cellular matrix production, proliferation, and apoptosis of endothelial progenitor cells in tissue-engineering scaffolds. Circulation. 2006;114:I193-1199.
13. Brown RA, Sethi KK, Gwanmesia I, Raemdonck D, Eastwood M, Mudera V. Enhanced fibroblast contraction of 3D collagen lattices and integrin expression by TGF-beta 1 and -beta 3: mechanoregulatory growth factors? Exp Cell Res. 2002;274 (2):310-322.
14. Simionescu A, Philips K, Vyavahare N. Elastin-derived peptides and TGF-beta 1 induce osteogenic responses in smooth muscle cells. Biochem Biophys Res Commun. 2005;334(2):524-532.
15. Altman GH, Diaz F, Jakuba C, Calabro T, Horan RL, Chen JS, et al. Silk-based biomaterials. Biomaterials. 2003;24(3):401-416.
16. Drury JL, Mooney DJ. Hydrogels for tissue engineering: scaffold design variables and applications. Biomaterials. 2003;24 (24):4337-4351.
17. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 2000;21(24):2529-2543.
18. Lee KY, Mooney DJ. Hydrogels for tissue engineering. Chem Rev. 2001;101(7):1869-1879.
19. Li WJ, Laurencin CT, Caterson EJ, Tuan RS, Ko FK. Electrospun nanofibrous structure: a novel scaffold for tissue engineering. J Biomed Mater Res. 2002;60(4):613-621.
20. Matthews JA, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen nanofibers. Biomacromolecules. 2002;3 (2):232-238.
21. Goldberg M, Langer R, Jia X. Nanostructured materials for applications in drug delivery and tissue engineering. J Biomater Sci Polym Ed. 2007;18(3):241-268.
22. Kim SS, Park MS, Jeon O, Choi CY, Kim BS. Poly(lactide-coglycolide)/hydroxyapatite composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(8):1399-1409.
23. Anderson DG, Burdick JA, Langer R. Materials science-smart biomaterials. Science. 2004;305(5692):1923-1924.
24. Hubbell JA. Biomaterials in tissue engineering. Bio-Technol. 1995;13(6):565-576.
25. Langer R, Tirrell DA. Designing materials for biology and medicine. Nature. 2004;428(6982):487-492.
26. Peppas NA, Langer R. New challenges in biomaterials. Science. 1994;263(5154):1715-1720.
27. Fernandes H, Moroni L, van Blitterswijk C, de Boer J. Extracellular matrix and tissue engineering applications. J Mater Chem. 2009;19(31):5474-5484.
28. Cannizzaro SM, Padera RF, Langer R, Rogers RA, Black FE, Davies MC, et al. A novel biotinylated degradable polymer for cellinteractive applications. Biotechnol Bioeng. 1998;58(5):529-535.
29. Wang DA, Ji J, Sun YH, Shen JC, Feng LX, Elisseeff JH. In situ immobilization of proteins and RGD peptide on polyurethane surfaces via poly(ethylene oxide) coupling polymers for human endothelial cell growth. Biomacromolecules. 2002;3(6):1286-1295.
30. Kong HJ, Hsiong S, Mooney DJ. Nanoscale cell adhesion lig and presentation regulates nonviral gene delivery and expression. Nano Lett. 2007;7(1):161-166.
31. Lateef SS, Boateng S, Hartman TJ, Crot CA, Russell B, Hanley L. GRGDSP peptide-bound silicone membranes withstand mechanical flexing in vitro and display enhanced fibroblast adhesion. Biomaterials. 2002;23(15):3159-3168.
32. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
33. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55(3):329-347.
34. Pitsillides CM, Joe EK, Wei XB, Anderson RR, Lin CP. Selective cell targeting with light-absorbing microparticles and nanoparticles. Biophys J. 2003;84(6):4023-4032.
35. Sarikaya M, Tamerler C, Jen AKY, Schulten K, Baneyx F. Molecular biomimetics: nanotechnology through biology. Nat Mater. 2003;2(9):577-585.
36. Chen RR, Silva EA, Yuen WW, Brock AA, Fischbach C, Lin AS, et al. Integrated approach to designing growth factor delivery systems. FASEB J. 2007;21(14):3896-3903.
37. Chen RR, Silva EA, Yuen WW, Mooney DJ. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm Res. 2007;24(2):258-264.
38. Nguyen KT, West JL. Photopolymerizable hydrogels for tissue engineering applications. Biomaterials. 2002;23(22):4307-4314.
39. Ratner BD, Bryant SJ. Biomaterials: where we have been and where we are going. Annu Rev Biomed Eng. 2004;6:41-75.
40. Silva EA, Mooney DJ. Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis. J Thromb Haemost. 2007;5(3):590-598.
41. Silva EA, Mooney DJ. Synthetic extracellular matrices for tissue engineering and regeneration. Curr Top Dev Biol. 2004;64:181-205.
42. Freed LE, Vunjaknovakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK, et al. Biodegradable polymer scaffolds for tissue engineering. Bio-Technol. 1994;12(7):689-693.
43. Agrawal CM, Ray RB. Biodegradable polymeric scaffolds for musculoskeletal tissue engineering. J Biomed Mater Res. 2001;55(2):141-150.
44. Hutmacher DW. Scaffold design and fabrication technologies for engineering tissues-state of the art and future perspectives. J Biomater Sci Polym Ed. 2001;12(1):107-124.
45. Kim BS, Mooney DJ. Development of biocompatible synthetic extracellular matrices for tissue engineering. Trends Biotechnol. 1998;16(5):224-230.
46. Li WJ, Tuli R, Okafor C, Derfoul A, Danielson KG, Hall DJ, et al. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. Biomaterials. 2005;26(6):599-609.
47. Xu CY, Inai R, Kotaki M, Ramakrishna S. Aligned biodegradable nanotibrous structure: a potential scaffold for blood vessel engineering. Biomaterials. 2004;25(5):877-886.
48. Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70(1-2):1-20.
49. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24.
50. Chau Y, Tan FE, Langer R. Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX. Bioconjug Chem. 2004;15(4):931-941.
51. Lutolf MR, Weber FE, Schmoekel HG, Schense JC, Kohler T, Muller R, et al. Repair of bone defects using synthetic mimetics of collagenous extracellular matrices. Nat Biotechnol. 2003;21(5):513-518.
52. Murthy N, Campbell J, Fausto N, Hoffman AS, Stayton PS. Bioinspired pH-responsive polymers for the intracellular delivery of biomolecular drugs. Bioconjug Chem. 2003;14(2):412-419.
53. Lee KY, Peters MC, Anderson KW, Mooney DJ. Controlled growth factor release from synthetic extracellular matrices. Nature. 2000;408(6815):998-1000.
54. Faury G, Garnier S, Weiss AS, Wallach J, Fulop T, Jacob MP, et al. Action of tropoelastin and synthetic elastin sequences on vascular tone and on free Ca2+ level in human vascular endothelial cells. Circ Res. 1998;82(3):328-336.
55. Li DY, Brooke B, Davis EC, Mecham RP, Sorensen LK, Boak BB, et al. Elastin is an essential determinant of arterial morphogenesis. Nature. 1998;393(6682):276-280.
56. Li DY, Faury G, Taylor DG, Davis EC, Boyle WA, Mecham RP, et al. Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest. 1998;102(10):1783-1787.
57. Robert L, Jacob MP, Fulop T. Elastin in blood vessels. Mol Biol Pathol Elastic Tissues. 1995;192:286-303.
58. Kielty CM, Sherratt MJ, Shuttleworth CA. Elastic fibres. J Cell Sci. 2002;115(14):2817-2828.
59. Wognum S, Schmidt DE, Sacks MS. On the mechanical role of de novo synthesized elastin in the urinary bladder wall. J Biomech Eng. 2009;131(10):101018.
60. Rahn DD, Acevedo JF, Word RA. Effect of vaginal distention on elastic fiber synthesis and matrix degradation in the vaginal wall: potential role in the pathogenesis of pelvic organ prolapse. Am J Physiol Regul Integr Comp Physiol. 2008;295(4):R1351-R1358.
61. Berglund JD, Nerem RM, Sambanis A. Incorporation of intact elastin scaffolds in tissue-engineered collagen-based vascular grafts. Tissue Eng. 2004;10(9-10):1526-1535.
62. Buijtenhuijs P, Buttafoco L, Poot AA, Daamen WF, van Kuppevelt TH, Dijkstra PJ, et al. Tissue engineering of blood vessels: characterization of smooth-muscle cells for culturing on collagen-andelastin-based scaffolds. Biotechnol Appl Biochem. 2004;39:141-149.
63. Daamen WF, van Moerkerk HTB, Hafmans T, Buttafoco L, Poot AA, Veerkamp JH, et al. Preparation and evaluation of molecularly-defined collagen-elastin-glycosaminoglycan scaffolds for tissue engineering. Biomaterials. 2003;24(22):4001-4009.
64. Daamen WF, Veerkamp JH, van Hest JCM, van Kuppevelt TH. Elastin as a biomaterial for tissue engineering. Biomaterials. 2007;28(30):4378-4398.
65. Leach JB, Wolinsky JB, Stone PJ, Wong JY. Crosslinked alphaelastin biomaterials: towards a processable elastin mimetic scaffold. Acta Biomater. 2005;1(2):155-164.
66. Almine JF, Bax DV, Mithieux SM, Nivison-Smith L, Rnjak J, Waterhouse A, et al. Elastin-based materials. Chem Soc Rev. 2010;39(9):3371-3379.
67. Mithieux SM, Rasko JEJ, Weiss AS. Synthetic elastin hydrogels derived from massive elastic assemblies of self-organized human protein monomers. Biomaterials. 2004;25(20):4921-4927.
68. Duca L, Floquet N, Alix AJP, Haye B, Debelle L. Elastin as a matrikine. Crit Rev Oncol Hematol. 2004;49(3):235-244.
69. Bashur CA, Venkataraman L, Ramamurthi A. Tissue engineering and regenerative strategies to replicate biocomplexity of vascular elastic matrix assembly tissue. Eng Part B Rev. 2012;18:203-217.
70. Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, et al. A critical role for elastin signaling in vascular morphogenesis and disease. Development. 2003;130(2):411-423.
71. Moore J, Thibeault S. Insights into the role of elastin in vocal fold health and disease. JVoice. 2011. doi:10.1016/j.jvoice.2011.05.003:7.
72. Jones PA, Scottburden T, Gevers W. Glycoprotein, elastin, and collagen secretion by rat smooth muscle cells. Proc Natl Acad Sci USA. 1979;76(1):353-357.
73. Sephel GC, Davidson JM. Elastin production in human skin fibroblast cultures and its decline with age. J Invest Dermatol. 1986;86(3):279-285.
74. Davidson JM. Smad about elastin regulation. Am J Respir Cell Mol Biol. 2002;26(2):164-166.
75. Suyama K, Nakamura F. Isolation and characterization of new cross-linking amino acid 'allodesmosine' from hydrolysate of elastin. Biochem Biophys Res Commun. 1990;170(2):713-718.
76. Brown-Augsburger P, Tisdale C, Broekelmann T, Sloan C, Mecham RP. Identification of an elastin cross-linking domain that joins three peptide chains. Possible role in nucleated assembly. J Biol Chem. 1995;270(30):17778-17783.
77. Swee MH, Parks WC, Pierce RA. Developmental regulation of elastin production. Expression of tropoelastin pre-mRNA persists after down-regulation of steady-state mRNA levels. J Biol Chem. 1995;270(25):14899-14906.
78. Hinek A, Mecham RP, Keeley F, Rabinovitch M. Impaired elastin fiber assembly related to reduced 67-kD elastin-binding protein in fetal lamb ductus arteriosus and in cultured aortic smoothmuscle cells treated with chondroitin sulfate. J Clin Invest. 1991;88(6):2083-2094.
79. Hinek A, Rabinovitch M. 67-kD Elastin-binding protein is a protective companion of extracellular insoluble elastin and intracellular tropoelastin. J Cell Biol. 1994;126(2):563-574.
80. Clarke AW, Wise SG, Cain SA, Kielty CM, Weiss AS. Coacervation is promoted by molecular interactions between the PF2 segment of fibrillin-1 and the domain 4 region of tropoelastin. Biochemistry. 2005;44(30):10271-10281.
81. Kagan HM, Li WD. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4):660-672.
82. Kothapalli CR, Ramamurthi A. Copper nanoparticle cues for biomimetic cellular assembly of crosslinked elastin fibers. Acta Biomater. 2009;5(2):541-553.
83. Sherratt MJ. Tissue elasticity and the ageing elastic fibre. Age (Dordr). 2009;31(4):305-325.
84. Sokolis DP. Passive mechanical properties and structure of the aorta: segmental analysis. Acta Physiol (Oxf). 2007;190 (4):277-289.
85. Armentano RL, Levenson J, Barra JG, Fischer EI, Breitbart GJ, Pichel RH, et al. Assessment of elastin and collagen contribution to aortic elasticity in conscious dogs. Am J Physiol. 1991;260(6Pt 2):H1870-H1877.
86. Kaartinen V, Warburton D. Fibrillin controls TGF-beta activation. Nat Genet. 2003;33(3):331-332.
87. Ono RN, Sengle G, Charbonneau NL, Carlberg V, Bachinger HP, Sasaki T, et al. Latent transforming growth factor beta-binding proteins and fibulins compete for fibrillin-1 and exhibit exquisite specificities in binding sites. J Biol Chem. 2009;284 (25):16872-16881.
88. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res. 2007;74(2):196-206.
89. Bax DV, Mahalingam Y, Cain S, Mellody K, Freeman L, Younger K, et al. Cell adhesion to fibrillin-1: identification of an Arg-Gly-Asp-dependent synergy region and a heparin-binding site that regulates focal adhesion formation. J Cell Sci. 2007;120(8):1383-1392.
90. Gibson MA. Microfibril-associated glycoprotein-1 (MAGP-1) and other non-fibrillin macromolecules which may possess a functional association with the 10nm microfibrils. Madame Curie Bioscience database. Austin TX: Landes Bioscience; 2000.
91. Yanagisawa H, Davis EC. Unraveling the mechanism of elastic fiber assembly: the roles of short fibulins. Int J Biochem Cell Biol. 2010;42(7):1084-1093.
92. Charbonneau NL, Ono RN, Corson GM, Keene DR, Sakai LY. Fine tuning of growth factor signals depends on fibrillin microfibril networks. Birth Defects Res C Embryo Today. 2004;72(1):37-50.
93. Chaudhry SS, Cain SA, Morgan A, Dallas SL, Shuttleworth CA, Kielty CM. Fibrillin-1 regulates the bioavailability of TGF beta 1. J Cell Biol. 2007;176(3):355-367.
94. Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, Sakai LY. Versican interacts with fibrillin-1 and links extracellular microfibrils to other connective tissue networks. J Biol Chem. 2002;277(6):4565-4572.
95. Kielty CM, Stephan S, Sherratt MJ, Williamson M, Shuttleworth CA. Applying elastic fibre biology in vascular tissue engineering. Philos Trans R Soc Lond B Biol Sci. 2007;362(1484):1293-1312.
96. Charbonneau NL, Dzamba BJ, Ono RN, Keene DR, Corson GM, Reinhardt DP, et al. Fibrillins can co-assemble in fibrils, but fibrillin fibril composition displays cell-specific differences. J Biol Chem. 2003;278(4):2740-2749.
97. Berk JL, Hatch CA, Morris SM, Stone PJ, Goldstein RH. Hypoxia suppresses elastin repair by rat lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005;289(6):L931-L936.
98. Gacchina CE, Ramamurthi A. Impact of pre-existing elastic matrix on TGFβ1 and HA oligomer-induced regenerative elastin repair by rat aortic smooth muscle cells. J Tissue Eng Regen Med. 2011;5(2):85-96.
99. Beamish JA, He P, Kottke-Marchant K, Marchant RE. Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev. 2010;16(5):467-491.
100. Kolodgie FD, Burke AP, Farb A, Weber DK, Kutys R, Wight TN, et al. Differential accumulation of proteoglycans and hyaluronan in culprit lesions: insights into plaque erosion. Arterioscler Thromb Vasc Biol. 2002;22(10):1642-1648.
101. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2004;24(3):429-434.
102. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14(5):617-623.
103. Lau AC, Duong TT, Ito S, Yeung RS. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum. 2008;58(3):854-863.
104. Chetty A, Cao GJ, Severgnini M, Simon A, Warburton R, Nielsen HC. Role of matrix metalloprotease-9 in hyperoxic injury in developing lung. Am J Physiol Lung Cell Mol Physiol. 2008;295(4): L584-L592.
105. Bressan GM, Pasqualironchetti I, Fornieri C, Mattioli F, Castellani I, Volpin D. Relevance of aggregation properties of tropoelastin to the assembly and structure of elastic fibers. J Ultrastruct Mol Struct Res. 1986;94(3):209-216.
106. Aikawa E, Aikawa M, Libby P, Figueiredo JL, Rusanescu G, Iwamoto Y, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009;119(13):1785-1794.
107. Senior RM, Griffin GL, Mecham RP. Chemotactic activity of elastin-derived peptides. J Clin Invest. 1980;66(4):859-862.
108. Debelle L, Tamburro AM. Elastin: molecular description and function. Int J Biochem Cell Biol. 1999;31(2):261-272.
109. Patel A, Fine B, Sandig M, Mequanint K. Elastin biosynthesis: the missing link in tissue-engineered blood vessels. Cardiovasc Res. 2006;71(1):40-49.
110. Wolfe BL, Rich CB, Goud HD, Terpstra AJ, Bashir M, Rosenbloom J, et al. Insulin-like growth factor-I regulates transcription of the elastin gene. J Biol Chem. 1993;268(17):12418-12426.
111. Zimmermann DR, Dourszimmerman MT, Brucknertuderman L, Schubert M. Versican is expressed in the proliferating zone in the epidermis and in association with the elastic network of the dermis. J Cell Biol. 1994;124(5):817-825.
112. Joddar B, Ibrahim S, Ramamurthi A. Impact of delivery mode of hyaluronan oligomers on elastogenic responses of adult vascular smooth muscle cells. Biomaterials. 2007;28(27):3918-3927.
113. Joddar B, Ramamurthi A. Fragment size- and dose-specific effects of hyaluronan on matrix synthesis by vascular smooth muscle cells. Biomaterials. 2006;27(15):2994-3004.
114. Joddar B, Ramamurthi A. Elastogenic effects of exogenous hyaluronan oligosaccharides on vascular smooth muscle cells. Biomaterials. 2006;27(33):5698-5707.
115. Kothapalli CR, Ramamurthi A. Benefits of concurrent delivery of hyaluronan and IGF-1 cues to regeneration of crosslinked elastin matrices by adult rat vascular cells. J Tissue Eng Regen Med. 2008;2(2-3):106-116.
116. Kothapalli CR, Ramamurthi A. Biomimetic regeneration of elastin matrices using hyaluronan and copper ion cues. Tissue Eng Part A. 2009;15(1):103-113.
117. Bashur CA, Ramamurthi A. Aligned electrospun scaffolds and elastogenic factors for vascular cell-mediated elastic matrix assembly. J Tissue Eng Regen Med. 2012. doi:10.1002/term.470.
118. Rucker RB, Kosonen T, Clegg MS, Mitchell AE, Rucker BR, Uriu-Hare JY, et al. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am J Clin Nutr. 1998;67(5):996S-1002S.
119. Kothapalli CR, Ramamurthi A. Lysyl oxidase enhances elastin synthesis and matrix formation by vascular smooth muscle cells. J Tissue Eng Regen Med. 2009;3(8):655-661.
120. Barone LM, Faris B, Chipman SD, Toselli P, Oakes BW, Franzblau C. Alteration of the extracellular matrix of smooth muscle cells by ascorbate treatment. Biochim Biophys Acta. 1985;840(2):245-254.
121. Bergethon PR, Mogayzel PJ, Franzblau C. Effect of the reducing environment on the accumulation of elastin and collagen in cultured smooth-muscle cells. Biochem J. 1989;258(1):279-284.
122. Davidson JM, LuValle PA, Zoia O, Quaglino D, Giro MG. Ascorbate differentially regulates elastin and collagen biosynthesis in vascular smooth muscle cells and skin fibroblasts by pretranslational mechanisms. J Biol Chem. 1997;272(1):345-352.
123. Dunn DM, Franzblau C. Effects of ascorbate on insoluble elastin accumulation and cross-link formation in rabbit pulmonary artery smooth muscle cultures. Biochemistry. 1982;21 (18):4195-4202.
124. Faris B, Ferrera R, Toselli P, Nambu J, Gonnerman WA, Franzblau C. Effect of varying amounts of ascorbate on collagen, elastin and lysyl oxidase synthesis in aortic smooth muscle cell cultures. Biochim Biophys Acta. 1984;797(1):71-75.
125. Keire PA, L'Heureux N, Vernon RB, Merrilees MJ, Starcher B, Okon E, et al. Expression of versican isoform V3 in the absence of ascorbate improves elastogenesis in engineered vascular constructs. Tissue Eng Part A. 2010;16(2):501-512.
126. Mitts TF, Bunda S, Wang Y, Hinek A. Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin. J Invest Dermatol. 2010;130 (10):2396-2406.
127. Coussens LM, Fingleton B, Matrisian LM. Cancer therapy- matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 2002;295(5564):2387-2392.
128. Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, et al. The TIMP2 membrane type 1 metalloproteinase receptor regulates the concentration and efficient activation of progelatinase A-a kinetic study. J Biol Chem. 1998;273 (2):871-880.
129. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or 3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro-TIMP-3 promotes apoptosis. J Clin Invest. 1998;101(6):1478-1487.
130. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets. 2009;10(12):1245-1254.
131. Baxter BT, Pearce WH, Waltke EA, Littooy FN, Hallett JW, Kent KC, et al. Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (phase II) multicenter study. J Vasc Surg. 2002;36 (1):1-12.
132. Bendeck MP, Conte M, Zhang MY, Nili N, Strauss BH, Farwell SM. Doxycycline modulates smooth muscle cell growth, migration, and matrix remodeling after arterial injury. Am J Pathol. 2002;160(3):1089-1095.
133. Maegdefessel L, Azuma J, Toh R, Merk DR, Deng A, Chin JT, et al. Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development. J Clin Invest. 2012;122(2):497-506.
134. Zhang P, Huang A, Ferruzzi J, Mecham RP, Starcher BC, Tellides G, et al. Inhibition of microRNA-29 enhances elastin levels in cells haploinsufficient for elastin and in bioengineered vessels- brief report. Arterioscler Thromb Vasc Biol. 2012;32(3):756-U501.
135. Maegdefessel L, Azuma J, Toh R, Deng A, Merk DR, Raiesdana A, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med. 2012;4(122):122ra22.
136. Safran SA, Gov N, Nicolas A, Schwarz US, Tlusty T. Physics of cell elasticity, shape and adhesion. Physica a-Stat Mech Applic. 2005;352(1):171-201.
137. Flemming RG, Murphy CJ, Abrams GA, Goodman SL, Nealey PF. Effects of synthetic micro- and nano-structured surfaces on cell behavior. Biomaterials. 1999;20(6):573-588.
138. Badylak SF, Valentin JE, Ravindra AK, McCabe GP, Stewart-Akers AM. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Eng Part A. 2008;14(11):1835-1842.
139. Nair LS, Laurencin CT. Biodegradable polymers as biomaterials. Prog Polym Sci. 2007;32(8-9):762-798.
140. Ju YM, Choi JS, Atala A, Yoo JJ, Lee SJ. Bilayered scaffold for engineering cellularized blood vessels. Biomaterials. 2010;31 (15):4313-4321.
141. Mark Saltzman W, Baldwin SP. Materials for protein delivery in tissue engineering. Adv Drug Deliv Rev. 1998;33(1-2):71-86.
142. Masters KS. Covalent growth factor immobilization strategies for tissue repair and regeneration. Macromol Biosci. 2011;11 (9):1149-1163.
143. Zeugolis DI, Khew ST, Yew ESY, Ekaputra AK, Tong YW, Yung LYL, et al. Electro-spinning of pure collagen nano-fibres-just an expensive way to make gelatin? Biomaterials. 2008;29(15):2293-2305.
144. Sell SA, McClure MJ, Garg K, Wolfe PS, Bowlin GL. Electrospinning of collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering. Adv Drug Deliv Rev 2009; 61:1007-1019
145. Ji W, Sun Y, Yang F, van den Beucken JJ, Fan M, Chen Z, et al. Bioactive electrospun scaffolds delivering growth factors and genes for tissue engineering applications. Pharm Res. 2011;28(6):1259-1272.
146. Sahoo S, Ang LT, Goh JC, Toh SL. Growth factor delivery through electrospun nanofibers in scaffolds for tissue engineering applications. J Biomed Mater Res A. 2010;93(4):1539-1550.
147. Chaikof EL, Matthew H, Kohn J, Mikos AG, Prestwich GD, Yip CM. Biomaterials and scaffolds in reparative medicine. Ann N Y Acad Sci. 2002;961:96-105.
148. Griffith LG, Naughton G. Tissue engineering-current challenges and expanding opportunities. Science. 2002;295(5557):1009-1014.
149. Huebsch N, Mooney DJ. Inspiration and application in the evolution of biomaterials. Nature. 2009;462(7272):426-432.
150. Lue J-M, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009;9 (4):325-341.
151. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9 (8):615-627.
152. Kamaly N, Xiao ZY, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971-3010.
153. Wang AZ, Gu F, Zhang L, Chan JM, Radovic-Moreno A, Shaikh MR, et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther. 2008;8(8):1063-1070.
154. Nguyen KT, Shukla KP, Moctezuma M, Braden ARC, Zhou J, Hu ZB, et al. Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cells. J Biomed Mater Res. 2009;88A (4):1022-1030.
155. Fahmy TM, Demento SL, Caplan MJ, Mellman I, Saltzman WM. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine. 2008;3(3):343-355.
156. Song CX, Labhasetwar V, Murphy H, Qu X, Humphrey WR, Shebuski RJ, et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Release. 1997;43(2-3):197-212.
157. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 2002;16 (10):1217-1226.
158. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010;10(7):2543-2548.
159. De Jong WH, Borm PJA. Drug delivery and nanoparticles: applications and hazards. Int J Nanomed. 2008;3(2):133-149.
160. Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, et al. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomed. 2011;6:2591-2605.
161. Cu Y, Saltzman WM. Controlled surface modification with poly (ethylene)glycol enhances diffusion of PLGA nanoparticles in human cervical mucus. Mol Pharm. 2009;6(1):173-181.
162. Cu Y, Saltzman WM. Drug delivery-stealth particles give mucus the slip. Nat Mater. 2009;8(1):11-13.
163. Nair LS, Laurencin CT. Polymers as biomaterials for tissue engineering and controlled drug delivery. Adv Biochem Engin/Biotechnol. 2006;102:47-90.
164. Yang SF, Leong KF, Du ZH, Chua CK. The design of scaffolds for use in tissue engineering. Part 1. Traditional factors. Tissue Eng. 2001;7(6):679-689.
165. Sarkar S, Lee GY, Wong JY, Desai TA. Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials. 2006;27(27):4775-4782.
166. Ahmann KA, Weinbaum JS, Johnson SL, Tranquillo RT. Fibrin degradation enhances vascular smooth muscle cell proliferation and matrix deposition in fibrin-based tissue constructs fabricated in vitro. Tissue Eng Part A. 2010;16(10):3261-3270.
167. Adair-Kirk TL, Senior RM. Fragments of extracellular matrix as mediators of inflammation. Int J Biochem Cell Biol. 2008;40(6-7):1101-1110.
168. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol. 2010;40(3):616-619.
169. Silva AKA, Richard C, Bessodes M, Scherman D, Merten OW. Growth factor delivery approaches in hydrogels. Biomacromolecules. 2009;10(1):9-18.
170. Nuttelman CR, Tripodi MC, Anseth KS. Dexamethasonefunctionalized gels induce osteogenic differentiation of encapsulated hMSCs. J Biomed Mater Res. 2006;76A(1):183-195.
171. Ibrahim S, Kothapalli CR, Kang QK, Ramamurthi A. Characterization of glycidyl methacrylate-crosslinked hyaluronan hydrogel scaffolds incorporating elastogenic hyaluronan oligomers. Acta Biomater. 2011;7(2):653-665.
172. Murphy WL, Peters MC, Kohn DH, Mooney DJ. Sustained release of vascular endothelial growth factor from mineralized poly(lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2000;21(24):2521-2527.
173. Hinek A, Wang Y, Liu K, Mitts TF, Jimenez F. Proteolytic digest derived from bovine ligamentum nuchae stimulates deposition of new elastin-enriched matrix in cultures and transplants of human dermal fibroblasts. J Dermatol Sci. 2005;39(3):155-166.
174. Daamen WF, Nillesen STM, Wismans RG, Reinhardt DP, Hafmans T, Veerkamp JH, et al. A biomaterial composed of collagen and solubilized elastin enhances angiogenesis and elastic fiber formation without calcification. Tissue Eng Part A. 2008;14(3):349-360.
175. Li M, Mondrinos MJ, Chen X, Gandhi MR, Ko FK, Lelkes PI. Co-electrospun poly(lactide-co-glycolide), gelatin, and elastin blends for tissue engineering scaffolds. J Biomed Mater Res. 2006;79A(4):963-973.
176. Stitzel J, Liu L, Lee SJ, Komura M, Berry J, Soker S, et al. Controlled fabrication of a biological vascular substitute. Biomaterials. 2006;27(7):1088-1094.
177. Ito S, Ishimaru S, Wilson SE. Effect of coacervated alpha-elastin on proliferation of vascular smooth muscle and endothelial cells. Angiology. 1998;49(4):289-297.
178. Ito S, Ishimaru S, Wilson SE. Inhibitory effect of type 1 collagen gel containing α-elastin on proliferation and migration of vascular smooth muscle and endothelial cells. Cardiovasc Surg. 1997;5 (2):176-183.
179. Miyamoto K, Atarashi M, Kadozono H, Shibata M, Koyama Y, Okai M, et al. Creation of cross-linked electrospun isotypicelastin fibers controlled cell-differentiation with new crosslinker. Int J Biol Macromol. 2009;45(1):33-41.
180. Fulop T, Khalil A, Larbi A. The role of elastin peptides in modulating the immune response in aging and age-related diseases. Pathol Biol. 2012;60(1):28-33.
181. Stephan S, Ball SG, Williamson M, Bax DV, Lomas A, Shuttleworth CA, et al. Cell-matrix biology in vascular tissue engineering. J Anat. 2006;209(4):495-502.
182. Sherratt MJ, Bax DV, Chaudhry SS, Hodson N, Lu JR, Saravanapavan P, et al. Substrate chemistry influences the morphology and biological function of adsorbed extra cellular matrix assemblies. Biomaterials. 2005;26(34):7192-7206.
183. Sherratt MJ, Holmes DF, Shuttleworth CA, Kielty CM. Substrate-dependent morphology of supramolecular assemblies: fibrillin and type-VI collagen microfibrils. Biophys J. 2004;86(5):3211-3222.
184. Miao M, Cirulis JT, Lee S, Keeley FW. Structural determinants of cross-linking and hydrophobic domains for self-assembly of elastin-like polypeptides. Biochemistry. 2005;44(43):14367-14375.
185. Yang GC, Woodhouse KA, Yip CM. Substrate-facilitated assembly of elastin-like peptides: studies by variable-temperature in situ atomic force microscopy. J Am Chem Soc. 2002;124(36):10648-10649.
186. Michael KE, Vernekar VN, Keselowsky BG, Meredith JC, Latour RA, Garcia AJ. Adsorption-induced conformational changes in fibronectin due to interactions with well-defined surface chemistries. Langmuir. 2003;19(19):8033-8040.
187. Mitsi M, Hong Z, Costello CE, Nugent MA. Heparin-mediated conformational changes in fibronectin expose vascular endothelial growth factor binding sites. Biochemistry. 2006;45(34):10319-10328.
188. Ma Z, Mao Z, Gao C. Surface modification and property analysis of biomedical polymers used for tissue engineering. Colloids Surf B Biointerfaces. 2007;60(2):137-157.
189. Mann BK, Schmedlen RH, West JL. Tethered-TGF-beta increases extra cellular matrix production of vascular smooth muscle cells. Biomaterials. 2001;22(5):439-444.
190. Solorio LD, Fu AS, Hernandez-Irizarry R, Alsberg E. Chondrogenic differentiation of human mesenchymal stem cell aggregates via controlled release of TGF-beta 1 from incorporated polymer microspheres. J Biomed Mater Res. 2010;92A(3):1139-1144.
191. Lu L, Stamatas GN, Mikos AG. Controlled release of transforming growth factor beta 1 from biodegradable polymer microparticles. J Biomed Mater Res. 2000;50(3):440-451.
192. Lu LC, Yaszemski MJ, Mikos AG. TGF-beta 1 release from biodegradable polymer microparticles: its effects on marrow stromal osteoblast function. J Bone Joint Surg Am. 2001;83A:S82-S91.
193. Peter SJ, Lu L, Kim DJ, Stamatas GN, Miller MJ, Yaszemski MJ, et al. Effects of transforming growth factor beta 1 released from biodegradable polymer microparticles on marrow stromal osteoblasts cultured on poly(propylene fumarate) substrates. J Biomed Mater Res. 2000;50(3):452-462.
194. Tanaka H, Sugita T, Yasunaga Y, Shimose S, Deie M, Kubo T, et al. Efficiency of magnetic liposomal transforming growth factorbeta 1 in the repair of articular cartilage defects in a rabbit model. J Biomed Mater Res. 2005;73A(3):255-263.
195. Gacchina CE, Deb PP, Barth JL, Ramamurthi A. Elastogenic inductability of smooth muscle cells from a rat model of late stage abdominal aortic aneurysms. Tissue Eng. 2011;17(13-14):1699-1711.
196. Venkataraman L, Ramamurthi A. Induced elastin matrix generation within 3-dimensional collagen scaffolds. Tissue Eng Part A. 2011;17:2879-2889.
197. Eley JG, Mathew P. Preparation and release characteristics of insulin and insulin-like growth factor-one from polymer nanoparticles. J Microencapsul. 2007;24(3):225-234.
198. Meinel L, Zoidis E, Zapf J, Hassa P, Hottiger MO, Auer JA, et al. Localized insulin-like growth factor I delivery to enhance new bone formation. Bone. 2003;33(4):660-672.
199. Hedberg EL, Shih CK, Solchaga LA, Caplan AI, Mikos AG. Controlled release of hyaluronan oligomers from biodegradable polymeric microparticle carriers. J Control Release. 2004;100 (2):257-266.
200. Mehta K, Sadeghi T, McQueen T, Lopez-Berestein G. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res. 1994;18(8):587-596.
201. Parthasarathy R, Mehta K. Altered metabolism of all-transretinoic acid in liposome-encapsulated form. Cancer Lett. 1998;134(2):121-128.
202. Patel P, Mundargi RC, Babu VR, Jain D, Rangaswamy V, Aminabhavi TM.Microencapsulation of doxycycline into poly(lactide-co-glycolide) by spray drying technique: effect of polymer molecular weight on process parameters. J Appl Polym Sci. 2008;108(6):4038-4046.
203. Patel RS, Cho DY, Tian C, Chang A, Estrellas KM, Lavin D, et al. Doxycycline delivery from PLGA microspheres prepared by a modified solvent removal method. J Microencapsul. 2012. doi:10.3109/02652048.2011.651499.
204. Wang X, Xu H, Zhao Y, Wang S, Abe H, Naito M, et al. Poly (lactide-co-glycolide) encapsulated hydroxyapatite microspheres for sustained release of doxycycline. Mater Sci Eng B. 2012;177 (4):367-372.
205. Mundargi RC, Srirangarajan S, Agnihotri SA, Patil SA, Ravindra S, Setty SB, et al. Development and evaluation of novel biodegradable microspheres based on poly(D, L-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies. J Control Release. 2007;119(1):59-68.
206. Sangare L, Morisset R, Gaboury L, Ravaoarinoro M. Effects of cationic liposome-encapsulated doxycycline on experimental Chlamydia trachomatis genital infection in mice. J Antimicrob Chemother. 2001;47(3):323-331.
207. Davies SR, Cole AA, Schmid TM. Doxycycline inhibits type X collagen synthesis in avian hypertrophic chondrocyte cultures. J Biol Chem. 1996;271(42):25966-25970.
208. TeKoppele JM, Beekman B, Verzijl N, Koopman JL, DeGroot J, Bank RA. Doxycycline inhibits collagen synthesis by differentiated articular chondrocytes. Adv Dent Res. 1998;12(2):63-67.
209. Ding R, McGuinness CL, Burnand KG, Sullivan E, Smith A. Matrix metalloproteinases in the aneurysm wall of patients treated with low-dose doxycycline. Vascular. 2005;13(5):290-297.
210. Prall AK, Longo GM, Mayhan WG, Waltke EA, Fleckten B, Thompson RW, et al. Doxycycline in patients with abdominal aortic aneurysms and in mice: comparison of serum levels and effect on aneurysm growth in mice. J Vasc Surg. 2002;35(5):923-928.
211. Curci JA, Mao DL, Bohner DG, Allen BT, Rubin BG, Reilly JM, et al. Preoperative treatment with doxycycline reduces aortic wall expression and activation of matrix metalloproteinases in patients with abdominal aortic aneurysms. J Vasc Surg. 2000;31(2):325-341.
212. Curci JA, Petrinec D, Liao SX, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998;28(6):1082-1093.
213. Piette M, Castagne D, Delattre L, Piel G. Preparation and evaluation of liposomes encapsulating synthetic MMP inhibitor (Ro 28-2653)-cyclodextrin complexes. J Incl Phenom Macrocycl Chem. 2007;57(1-4):101-103.
214. Anand S, Majeti BK, Acevedo LM, Murphy EA, Mukthavaram R, Scheppke L, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16(8):909-914.
215. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 2010;18(9):1650-1656.
216. Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J Biomed Mater Res. 2002;61(2):180-187.
217. Hickey T, Kreutzer D, Burgess DJ, Moussy F. Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices. Biomaterials. 2002;23(7):1649-1656.
218. Gómez-Gaete C, Fattal E, Silva L, Besnard M, Tsapis N. Dexamethasone acetate encapsulation into Trojan particles. J Control Release. 2008;128(1):41-49.
219. Gómez-Gaete C, Tsapis N, Besnard M, Bochot A, Fattal E. Encapsulation of dexamethasone into biodegradable polymeric nanoparticles. Int J Pharm. 2007;331(2):153-159.
220. Hegeman MA, Cobelens PM, Kamps JAAM, Hennus MP, Jansen NJG, Schultz MJ, et al. Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation. Br J Pharmacol. 2011;163(5):1048-1058.
221. Jordan RE, Hewitt N, Lewis W, Kagan H, Franzbla C. Regulation of elastase-catalyzed hydrolysis of insoluble elastin by synthetic and naturally occurring hydrophobic ligands. Biochemistry. 1974;13(17):3497-3503.
222. Kagan HM, Jordan RE, Crombie GD, Lewis W, Franzbla C. Proteolysis of elastin-ligand complexes. Stimulation of elastase digestion of insoluble elastin by sodium dodecyl sulfate. Biochemistry. 1972;11(18):3412-3418.
223. Gertler A. The non-specific electrostatic nature of the adsorption of elastase and other basic proteins on elastin. Eur J Biochem. 1971;20(4):541-546.
224. Kagan HM, Simpson DE, Tseng L. Substrate-directed modulation of elastin oxidation by lysyl oxidase. Connect Tissue Res. 1981;8 (3-4):213-217.
225. Kagan HM, Tseng L, Simpson DE. Control of elastin metabolism by elastin ligands. Reciprocal effects on lysyl oxidase activity. J Biol Chem. 1981;256(11):5417-5421.
226. Kagan HM, Sullivan KA, Olsson TA, Cronlund AL. Purification and properties of four species of lysyl oxidase from bovine aorta. Biochem J. 1979;177(1):203-214.
227. Buck CA, Horwitz AF. Cell surface receptors for extracellular matrix molecules. Annu Rev Cell Biol. 1987;3:179-205.
228. Hersel U, Dahmen C, Kessler H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003;24(24):4385-4415.
229. Ohta K, Yamaguchi J, Akimoto M, Fukushima K, Suwa T, Awazu S. Retention mechanism of imidazoles in connective tissue. 1. Binding to elastin. Drug Metab Dispos. 1996;24 (12):1291-1297.
230. Oitate M, Hirota T, Murai T, Miura S-i, Ikeda T. Covalent binding of rofecoxib, but not other cyclooxygenase-2 inhibitors, to allysine aldehyde in elastin of human aorta. Drug Metab Dispos. 2007;35(10):1846-1852.
231. Oitate M, Hirota T, Takahashi M, Murai T, Miura S-i, Senoo A, et al. Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther. 2007;320(3):1195-1203.
232. Lutolf MP, Lauer-Fields JL, Schmoekel HG, Metters AT, Weber FE, Fields GB, et al. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc Natl Acad Sci USA. 2003;100 (9):5413-5418.
233. Seliktar D, Zisch AH, Lutolf MP, Wrana JL, Hubbell JA. MMP-2 sensitive, VEGF-bearing bioactive hydrogels for promotion of vascular healing. J Biomed Mater Res. 2004;68A(4):704-716.
234. Banerjee J, Hanson AJ, Gadam B, Elegbede AI, Tobwala S, Ganguly B, et al. Release of liposomal contents by cell-secreted matrix metalloproteinase-9. Bioconjug Chem. 2009;20(7):1332-1339.
235. Elegbede AI, Banerjee J, Hanson AJ, Tobwala S, Ganguli B, Wang R, et al. Mechanistic studies of the triggered release of liposomal contents by matrix metalloproteinase-9. J Am Chem Soc. 2008;130(32):10633-10642.
236. Hatakeyama H, Akita H, Ishida E, Hashimoto K, Kobayashi H, Aoki T, et al. Tumor targeting of doxorubicin by anti-MT1-MMP antibody modified PEG liposomes. Int J Pharm. 2007;342(1-2):194-200.
237. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14(1):68-77.
238. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinomaselective targeting. J Control Release. 2006;111(3):333-342.
239. D'Armiento J. Decreased elastin in vessel walls puts the pressure on. J Clin Invest. 2003;112(9):1308-1310.
240. Davis EC. Smooth muscle cell to elastic lamina connections in developing mouse aorta: role in aortic medial organization. Lab Invest. 1993;68(1):89-99.
241. Gacchina CE, Brothers TE, Ramamurthi A. Evaluating smooth muscle cells from CaCl2-induced rat aortal expansions as a surrogate culture model for study of elastogenic induction of human aneurysmal cells. Tissue Eng. 2011;17:1945-1948.
242. Bax DV, Bernard SE, Lomas A, Morgan A, Humphries J, Shuttleworth CA, et al. Cell adhesion to fibrillin-1 molecules and microfibrils is mediated by alpha(5)beta(1) and alpha(v) beta(3) integrins. J Biol Chem. 2003;278(36):34605-34616.
243. Lomas AC, Mellody KT, Freeman LJ, Bax DV, Shuttleworth CA, Kielty CM. Fibulin-5 binds human smooth-muscle cells through alpha 5 beta 1 and alpha 4 beta 1 integrins, but does not support receptor activation. Biochem J. 2007;405:417-428.
244. Zhang Z, Wang ZX, Liu SQ, Kodama M. Pore size, tissue ingrowth, and endothelialization of small-diameter microporous polyurethane vascular prostheses. Biomaterials. 2004;25(1):177-187.
245. Kannan RY, Salacinski HJ, Butler PE, Hamilton G, Seifalian AM. Current status of prosthetic bypass grafts: a review. J Biomed Mater Res B Appl Biomater. 2005;74B(1):570-581.
246. Niklason LE, Gao J, Abbott WM, Hirschi KK, Houser S, Marini R, et al. Functional arteries grown in vitro. Science. 1999;284 (5413):489-493.
247. Mitchell SL, Niklason LE. Requirements for growing tissueengineered vascular grafts. Cardiovasc Pathol. 2003;12(2):59-64.
248. L'Heureux N, Stoclet JC, Auger FA, Lagaud GJL, Germain L, Andriantsitohaina R. A human tissue-engineered vascular media: a new model for pharmacological studies of contractile responses. FASEB J. 2001;15(2):515-524.
249. L'Heureux N, Germain L, Labbe R, Auger FA. In vitro construction of a human blood vessel from cultured vascular cells. J Vasc Surg. 1993;17(3):499-509.
250. Martin ND, Schaner PJ, Tulenko TN, Shapiro IM, DiMatteo CA, Williams TK, et al. In vivo behavior of decellularized vein allograft. J Surg Res. 2005;129(1):17-23.
251. Schaner PJ, Martin ND, Tulenko TN, Shapiro IM, Tarola NA, Leichter RF, et al. Decellularized vein as a potential scaffold for vascular tissue engineering. J Vasc Surg. 2004;40(1):146-153.
252. Faury G, Ristori MT, Verdetti J, Jacob MP, Robert L. Effect of elastin peptides on vascular tone. J Vasc Res. 1995;32(2):112-119.
253. Robb BW, Wachi H, Schaub T, Mecham RP, Davis EC. Characterization of an in vitro model off elastic fiber assembly. Mol Biol Cell. 1999;10(11):3595-3605.
254. Nivison-Smith L, Rnjak J, Weiss AS. Synthetic human elastin microfibers: stable cross-linked tropoelastin and cell interactive constructs for tissue engineering applications. Acta Biomater. 2010;6(2):354-359.
255. Nivison-Smith L, Weiss AS. Alignment of human vascular smooth muscle cells on parallel electrospun synthetic elastin fibers. J Biomed Mater Res. 2012;100A(1):155-161.
256. Mann BK, West JL. Cell adhesion peptides alter smooth muscle cell adhesion, proliferation, migration, and matrix protein synthesis on modified surfaces and in polymer scaffolds. J Biomed Mater Res. 2002;60(1):86-93.
257. Haider M, Leung V, Ferrari F, Crissman J, Powell J, Cappello J, et al. Molecular engineering of silk-elastinlike polymers for matrixmediated gene delivery: biosynthesis and characterization. Mol Pharm. 2005;2(2):139-150.
258. Herrero-Vanrell R, Rincon AC, Alonso M, Reboto V, Molina-Martinez IT, Rodriguez-Cabello JC. Self-assembled particles of an elastin-like polymer as vehicles for controlled drug release. J Control Release. 2005;102(1):113-122.
259. Ghosh J, Murphy MO, Turner N, Khwaja N, Halka A, Kielty CM, et al. The role of transforming growth factor beta(1) in the vascular system. Cardiovasc Pathol. 2005;14(1):28-36.
260. Long JL, Tranquillo RT. Elastic fiber production in cardiovascular tissue-equivalents. Matrix Biol. 2003;22(4):339-350.
261. Swartz DD, Russell JA, Andreadis ST. Engineering of fibrinbased functional and implantable small-diameter blood vessels. Am J Physiol Heart Circ Physiol. 2005;288(3):H1451-H1460.
262. Labhasetwar V, Song CX, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modifications. J Pharm Sci. 1998;87(10):1229-1234.
263. Guzman LA, Labhasetwar V, Song CX, Jang YS, Lincoff AM, Levy R, et al. Local intraluminal infusion of biodegradable polymeric nanoparticles-a novel approach for prolonged drug delivery after balloon angioplasty. Circulation. 1996;94(6):1441-1448.
264. Starcher BC. Lung elastin and matrix. Chest. 2000;117(5):229S-234S.
265. Wise SG, Mithieux SM, Weiss AS. Engineered tropoelastin and elastin-based biomaterials. In: McPherson A, editor. Advances in protein chemistry and structural biology, vol 78. Elsevier Books, San Diego; 2009. p. 1-24.
266. Pierce RA, Mariani TJ, Senior RM. Elastin in lung development and disease. In: Chadwick DJGJA, editor. Molecular biology and pathology of elastic tissues. Chichester, UK, Wiley; 1995. p. 199-214.
267. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: multiple, multifarious, and multifaceted. Physiol Rev. 2007;87(1):69-98.
268. Wood JR, Bellamy D, Child AH, Citron KM. Pulmonary disease in patients with Marfan syndrome. Thorax. 1984;39(10):780-784.
269. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol. 1990;259(4):L159-L184.
270. Kuhn C. Repairing the cables of the lung. Am J Respir Cell Mol Biol. 1997;17(3):287-288.
271. Orens JB, Garrity Jr ER. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc. 2009;6 (1):13-19.
272. Andrade CF, Wong AP, Waddell TK, Keshavjee S, Liu MY. Cellbased tissue engineering for lung regeneration. Am J Physiol Lung Cell Mol Physiol. 2007;292(2):L510-L518.
273. Cortiella J, Nichols JE, Kojima K, Bonassar LJ, Dargon P, Roy AK, et al. Tissue-engineered lung: an in vivo and in vitro comparison of polyglycolic acid and pluronic F-127 hydrogel/somatic lung progenitor cell constructs to support tissue growth. Tissue Eng. 2006;12(5):1213-1225.
274. Mondrinos MJ, Koutzaki S, Jiwanmall E, Li MY, Dechadarevian JP, Lelkes PI, et al. Engineering three-dimensional pulmonary tissue constructs. Tissue Eng. 2006;12(4):717-728.
275. Price AP, England KA, Matson AM, Blazar BR, Panoskaltsis-Mortari A. Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A. 2010;16(8):2581-2591.
276. Petersen TH, Calle EA, Zhao L, Lee EJ, Gui L, Raredon MB, et al. Tissue-engineered lungs for in vivo implantation. Science. 2010;329(5991):538-541.
277. Rippon HJ, Lane S, Qin M, Ismail NS, Wilson MR, Takata M, et al. Embryonic stem cells as a source of pulmonary epithelium in vitro and in vivo. Proc Am Thorac Soc. 2008;5(6):717-722.
278. Wang DC, Morales JE, Calame DG, Alcorn JL, Wetsel RA. Transplantation of human embryonic stem cell-derived alveolar epithelial type II cells abrogates acute lung injury in mice. Mol Ther. 2010;18(3):625-634.
279. Yu JY, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318(5858):1917-1920.
280. Nichols JE, Niles JA, Cortiella J. Design and development of tissue engineered lung: progress and challenges. Organogenesis. 2009;5(2):57-61.
281. Lanone S, Zheng T, Zhu Z, Liu W, Lee CG, Ma B, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and-12 in IL-13-induced inflammation and remodeling. J Clin Invest. 2002;110(4):463-474.
282. Vandenbroucke RE, Dejonckheere E, Libert C. A therapeutic role for matrix metalloproteinase inhibitors in lung diseases? Eur Respir J. 2011;38(5):1200-1214.
283. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol Lung Cell Mol Physiol. 1996;270(2):L305-L310.
284. Massaro GD, Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997;3(6):675-677.
285. Mariani TJ, Sandefur S, Pierce RA. Elastin in lung development. Exp Lung Res. 1997;23(2):131-145.
286. Azarmi S, Roa WH, Loebenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60(8):863-875.
287. Bailey MM, Berkland CJ. Nanoparticle formulations in pulmonary drug delivery. Med Res Rev. 2009;29(1):196-212.
288. Ely L, Roa W, Finlay WH, Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm. 2007;65(3):346-353.
289. Mastrandrea LD, Quattrin T. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev. 2006;58(9-10):1061-1075.
290. Quattrin T. Inhaled insulin: recent advances in the therapy of type 1 and 2 diabetes. Expert Opin Pharmacother. 2004;5(12):2597-2604.
291. Bosquillon C, Lombry C, Préat V, Vanbever R. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Release. 2001;70(3):329-339.
292. Edwards DA, Hanes J, Caponetti G, Hrkach J, BenJebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276(5320):1868-1871.
293. Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA. 2002;99(19):12001-1205.
294. Moller W, Hofer T, Ziesenis A, Karg E, Heyder J. Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol Appl Pharmacol. 2002;182(3):197-207.
295. Sayes CM, Reed KL, Warheit DB. Assessing toxicity of fine and nanoparticles: comparing in vitro measurements to in vivo pulmonary toxicity profiles. Toxicol Sci. 2007;97(1):163-180.
296. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 2003;52(6):981-986.
297. Sharma A, Sharma S, Khuller GK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 2004;54(4):761-766.
298. Foster KA, Yazdanian M, Audus KL. Microparticulate uptake mechanisms of in-vitro cell culture models of the respiratory epithelium. J Pharm Pharmacol. 2001;53(1):57-66.
299. Fink TL, Klepcyk PJ, Oette S, Gedeon CR, Hyatt SL, Kowalczyk TH, et al. Plasmid size up to 20 kbp does not limit effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene Ther. 2006;13(13):1048-1051.
300. Fenner DE, Hsu Y. Pathophysiology of the pelvic floor: basic physiology, effects of ageing, and menopausal changes pelvic floor disorders. In: Santoro GA, Wieczorek AP, Bartram CI, editors. Springer, Milan; 2010. p. 25-32.
301. Drewes PG, Yanagisawa H, Starcher B, Hornstra I, Csiszar K, Marinis SI, et al. Pelvic organ prolapse in fibulin-5 knockout mice-pregnancy-induced changes in elastic fiber homeostasis in mouse vagina. Am J Pathol. 2007;170(2):578-589.
302. Weber AM, Richter HE. Pelvic organ prolapse. Obstet Gynecol. 2005;106(3):615-634.
303. Jelovsek JE, Barber MD, Paraiso MFR, Walters MD. Functional bowel and anorectal disorders in patients with pelvic organ prolapse and incontinence. Am J Obstet Gynecol. 2005;193(6):2105-2111.
304. Bump RC, Norton PA. Epidemiology and natural history of pelvic floor dysfunction. Obstet Gynecol Clin North Am. 1998;25(4):723.
305. Liu XQ, Zhao Y, Gao JG, Pawlyk B, Starcher B, Spencer JA, et al. Elastic fiber homeostasis requires lysyl oxidase-like 1 protein. Nat Genet. 2004;36(2):178-182.
306. Liu XQ, Zhao Y, Pawlyk B, Damaser M, Li TS. Failure of elastic fiber homeostasis leads to pelvic floor disorders. Am J Pathol. 2006;168(2):519-528.
307. Nakamura T, Lozano PR, Ikeda Y, Iwanaga Y, Hinek A, Minamisawa S, et al. Fibulin-5/DANCE is essential for elastogenesis in vivo. Nature. 2002;415(6868):171-175.
308. Yanagisawa H, Davis EC, Starcher BC, Ouchi T, Yanagisawa M, Richardson JA, et al. Fibulin-5 is an elastin-binding protein essential for elastic fibre development in vivo. Nature. 2002;415 (6868):168-171.
309. Mallipeddi R, Rohan LC. Nanoparticle-based vaginal drug delivery systems for HIV prevention. Expert Opin Drug Deliv. 2010;7 (1):37-48.
310. Lai SK, O'Hanlon DE, Harrold S, Man ST, Wang Y-Y, Cone R, et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc Natl Acad Sci USA. 2007;104 (5):1482-1487.
311. Lai SK, Wang Y-Y, Hanes J. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev. 2009;61(2):158-171.
312. Gray SD, Titze IR, Alipour F, Hammond TH. Biomechanical and histologic observations of vocal fold fibrous proteins. Ann Otol Rhinol Laryngol. 2000;109(1):77-85.
313. Hirano M. Structure of the vocal fold in normal and disease states. Anatomical and physical study. ASHA Rep. 1981;11:11-30.
314. Hahn MS, Kobler JB, Starcher BC, Zeitels SM, Langer R. Quantitative and comparative studies of the vocal fold extracellular matrix- I: elastic fibers and hyaluronic acid. Ann Otol Rhinol Laryngol. 2006;115(2):156-164.
315. Sato K, Hirano M. Age-related changes of the macula flava of the human vocal fold. Ann Otol Rhinol Laryngol. 1995;104(11):839-844.
316. Sato K, Hirano M. Histologic investigation of the macula flava of the human vocal fold. Ann Otol Rhinol Laryngol. 1995;104 (2):138-143.
317. Ding H, Gray SD. Senescent expression of genes coding tropoelastin, elastase, lysyl oxidase, and tissue inhibitors of metalloproteinases in rat vocal folds: comparison with skin and lungs. J Speech Lang Hear Res. 2001;44(2):317-326.
318. Rousseau B, Hirano S, Scheidt TD, Welham NV, Thibeault SL, Chan RW, et al. Characterization of vocal fold scarring in a canine model. Laryngoscope. 2003;113(4):620-627.
319. Thibeault SL, Gray SD, Bless DM, Chan RW, Ford CN. Histologic and rheologic characterization of vocal fold scarring. J Voice. 2002;16(1):96-104.
320. Hirano S. Current treatment of vocal fold scarring. Curr Opin Otolaryngol Head Neck Surg. 2005;13(3):143-147.
321. Zeitels SM, Hillman RE, Mauri M, Desloge R, Doyle PB. Phonomicrosurgery in singers and performing artists: treatment outcomes, management theories, and future directions. Ann Otol Rhinol Laryngol. 2002;111(12):21-40.
322. Chhetri DK, Head C, Revazova E, Hart S, Bhuta S, Berke GS. Lamina propria replacement therapy with cultured autologous fibroblasts for vocal fold scars. Otolaryngol Head Neck Surg. 2004;131(6):864-870.
323. Kolachala VL, Henriquez OA, Shams S, Golub JS, Kim Y-t, Laroui H, et al. Slow-release nanoparticle-encapsulated delivery system for laryngeal injection. Laryngoscope. 2010;120(5):988-994.
324. Mortensen M, Woo P. Office steroid injections of the larynx. Laryngoscope. 2006;116(10):1735-1739.
325. Hirano S, Thibeault S, Bless DM, Ford CN, Kanemaru SI. Hepatocyte growth factor and its receptor c-Met in rat and rabbit vocal folds. Ann Otol Rhinol Laryngol. 2002;111 (8):661-666.
326. Hirano S, Bless DM, Heisey D, Ford CN. Effect of growth factors on hyaluronan production by canine vocal fold fibroblasts. Ann Otol Rhinol Laryngol. 2003;112(7):617-624.
327. Hirano S, Bless D, Heisey D, Ford C. Roles of hepatocyte growth factor and transforming growth factor beta 1 in production of extracellular matrix by canine vocal fold fibroblasts. Laryngoscope. 2003;113(1):144-148.
328. Hirano S, Bless DM, Massey RJ, Hartig GK, Ford CN. Morphological and functional changes of human vocal fold fibroblasts with hepatocyte growth factor. Ann Otol Rhinol Laryngol. 2003;112(12):1026-1033.
329. Luo Y, Kobler JB, Zeitels SM, Langer R. Effects of growth factors on extracellular matrix production by vocal fold fibroblasts in 3-dimensional culture. Tissue Eng. 2006;12(12):3365-3374.
330. Hirano S, Bless DM, Rousseau B, Welham N, Montequin D, Chan RW, et al. Prevention of vocal fold scarring by topical injection of hepatocyte growth factor in a rabbit model. Laryngoscope. 2004;114(3):548-556.
331. Duflo S, Thibeault SL, Li W, Shu XZ, Prestwich GD. Vocal fold tissue repair in vivo using a synthetic extracellular matrix. Tissue Eng. 2006;12(8):2171-2180.
332. Grieshaber SE, Farran AJE, Lin-Gibson S, Kiick KL, Jia X. Synthesis and characterization of elastin-mimetic hybrid polymers with multiblock, alternating molecular architecture and elastomeric properties. Macromolecules. 2009;42(7):2532-2541.
333. Long JL, Neubauer J, Zhang Z, Zuk P, Berke GS, Chhetri DK. Functional testing of a tissue-engineered vocal fold cover replacement. Otolaryngol Head Neck Surg. 2010;142(3):438-440.
334. Park H, Karajanagi S, Wolak K, Aanestad J, Daheron L, Kobler JB, et al. Three-dimensional hydrogel model using adiposederived stem cells for vocal fold augmentation. Tissue Eng Part A. 2010;16(2):535-543.
335. Taipale J, Saharinen J, Hedman K, KeskiOja J. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem. 1996;44(8):875-889.
336. Reinhardt DP, Sasaki T, Dzamba BJ, Keene DR, Chu ML, Gohring W, et al. Fibrillin-1 and fibulin-2 interact and are colocalized in some tissues. J Biol Chem. 1996;271(32):19489-19496.
337. Abrams WR, Ma RI, Kucich U, Bashir MM, Decker S, Tsipouras P, et al. Molecular cloning of the microfibrillar protein MFAP3 and assignment of the gene to human chromosome 5q32-q33.2. Genomics. 1995;26(1):47-54.
338. Hirano E, Fujimoto N, Tajima S, Akiyama M, Ishibashi A, Kobayashi R, et al. Expression of 36-kDa microfibril-associated glycoprotein (MAGP-36) in human keratinocytes and its localization in skin. J Dermatol Sci. 2002;28(1):60-67.
339. Horrigan SK, Rich CB, Streeten BW, Li ZY, Foster JA. Characterization of an associated microfibril protein through recombinant DNA techniques. J Biol Chem. 1992;267(14):10087-10095.
340. Lausen M, Lynch N, Schlosser A, Tornoe I, Saekmose SG, Teisner B, et al. Microfibril-associated protein 4 is present in lung washings and binds to the collagen region of lung surfactant protein D. J Biol Chem. 1999;274(45):32234-32240.
341. Liu WG, Faraco J, Qian CP, Francke U. The gene for microfibrilassociated protein-1 (MFAP1) is located several megabases centromeric to FBN1 and is not mutated in Marfan syndrome. Hum Genet. 1997;99(5):578-584.
342. Toyoshima T, Yamashita K, Furuichi H, Shishibori T, Itano T, Kobayashi R. Ultrastructural distribution of 36-kD microfibrilassociated glycoprotein (MAGP-36) in human and bovine tissues. J Histochem Cytochem. 1999;47(8):1049-1056.
343. Clark R, Singer A. Wound repair: basic biology to tissue engineering. In: Lanza R, Langer R, Vacanti JP, editors. Principles of tissue engineering 2. San Diego: Academic Press; 2000. p. 855-878.
344. Parenteau N, Hardin-Young J, Ross R. Skin. In: Lanza R, Langer R, Vacanti JP, editors. Principles of tissue engineering 2. San Diego: Academic Press; 2000. p. 879-87.
345. Amadeu TP, Braune AS, Porto LC, Desmouliere A, Costa AMA. Fibrillin-1 and elastin are differentially expressed in hypertrophic scars and keloids. Wound Repair Regen. 2004;12(2):169-174.
346. Roten SV, Bhat S, Bhawan J. Elastic fibers in scar tissue. J Cutan Pathol. 1996;23(1):37-42.
347. Chen G, Chen J, Zhuo S, Xiong S, Zeng H, Jiang X, et al. Nonlinear spectral imaging of human hypertrophic scar based on two-photon excited fluorescence and second-harmonic generation. Br J Dermatol. 2009;161(1):48-55.
348. Tsuji T, Sawabe M. Elastic fibers in scar tissue: scanning and transmission electron microscopic studies. J Cutan Pathol. 1987;14(2):106-113.
349. Giro MG, Oikarinen AI, Oikarinen H, Sephel G, Uitto J, Davidson JM. Demonstration of elastin gene expression in human skin fibroblast cultures and reduced tropoelastin production by cells from a patient with atrophoderma. J Clin Invest. 1985;75(2):672-678.
350. Lamme EN, van Leeuwen RTJ, Jonker A, vanMarle J, Middelkoop E. Living skin substitutes: survival and function of fibroblasts seeded in a dermal substitute in experimental wounds. J Invest Dermatol. 1998;111(6):989-995.
351. Jones I, Currie L, Martin R. A guide to biological skin substitutes. Br J Plast Surg. 2002;55(3):185-193.
352. Casasco M, Casasco A, Comaglia AI, Farina A, Calligaro A. Differential distribution of elastic tissue in human natural skin and tissue-engineered skin. J Mol Histol. 2004;35(4):421-428.
353. Rnjak J, Wise SG, Mithieux SM, Weiss AS. Severe burn injuries and the role of elastin in the design of dermal substitutes. Tissue Eng Part B Rev. 2011;17(2):81-91.
354. Devries HJC, Zeegelaar JE, Middelkoop E, Gijsbers G, Vanmarle J, Wildevuur CHR, et al. Reduced wound contraction and scar formation in punch biopsy wounds. Native collagen dermal substitutes. A clinical study. Br J Dermatol. 1995;132(5):690-697.
355. Lamme EN, de Vries HJC, van Veen H, Gabbiani G, Westerhof W, Middelkoop E. Extracellular matrix characterization during healing of full-thickness wounds treated with a collagen/elastin dermal substitute shows improved skin regeneration in pigs. J Histochem Cytochem. 1996;44(11):1311-1322.
356. de Vries HJ, Middelkoop E, Mekkes JR, Dutrieux RP, Wildevuur CH, Westerhof H. Dermal regeneration in native non-cross-linked collagen sponges with different extracellular matrix molecules. Wound Repair Regen. 1994;2(1):37-47.
357. Raghunath M, Bachi T, Meuli M, Altermatt S, Gobet R, BrucknerTuderman L, et al. Fibrillin and elastin expression in skin regenerating from cultured keratinocyte autografts: morphogenesis ofmicrofibrils begins at the dermo-epidermal junction and precedes elastic fiber formation. J Invest Dermatol. 1996;106(5):1090-1095.
358. van Zuijlen PPM, van Trier AJM, Vloemans J, Groenevelt F, Kreis RW, Middelkoop E. Graft survival and effectiveness of dermal substitution in burns and reconstructive surgery in a one-stage grafting model. Plast Reconstr Surg. 2000;106(3):615-623.
359. Haslik W, Kamolz LP, Nathschlaeger G, Andel H, Meissl G, Frey M. First experiences with the collagen-elastin matrix Matriderm ((R)) as a dermal substitute in severe burn injuries of the hand. Burns. 2007;33(3):364-368.
360. Prow TW, Grice JE, Lin LL, Faye R, Butler M, Becker W, et al. Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev. 2011;63(6):470-491.
361. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm. 2007;328(2):191-195.
362. Maia CS, Mehnert W, Schaller M, Korting HC, Gysler A, Haberland A, et al. Drug targeting by solid lipid nanoparticles for dermal use. J Drug Target. 2002;10(6):489-495.
363. Chen HB, Chang XL, Du DR, Liu W, Liu J, Weng T, et al. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release. 2006;110(2):296-306.
364. Kuntsche J, Bunjes H, Fahr A, Pappinen S, Rönkkö S, Suhonen M, et al. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int J Pharm. 2008;354(1-2):180-195.
365. Castro GA, Coelho ALLR, Oliveira CA, Mahecha GAB, Oréfice RL, Ferreira LAM. Formation of ion pairing as an alternative to improve encapsulation and stability and to reduce skin irritation of retinoic acid loaded in solid lipid nanoparticles. Int J Pharm. 2009;381(1):77-83.
366. Mandawgade SD, Patravale VB. Development of SLNs from natural lipids: application to topical delivery of tretinoin. Int J Pharm. 2008;363(1-2):132-138.
367. Shah KA, Date AA, Joshi MD, Patravale VB. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm. 2007;345(1-2):163-171.
368. Aitken KJ, Bagli DJ. The bladder extracellular matrix. Part I: architecture, development and disease. Nat Rev Urol. 2009;6 (11):596-611.
369. Aitken KJ, Bagli DJ. The bladder extracellular matrix. Part II: regenerative applications. Nat Rev Urol. 2009;6(11):612-621.
370. Murakumo M, Ushiki T, Abe K, Matsumura K, Shinno Y, Koyanagi T. Three-dimensional arrangement of collagen and elastin fibers in the human urinary bladder: a scanning electron microscopic study. J Urol. 1995;154(1):251-256.
371. Korossis S, Bolland F, Ingham E, Fisher J, Kearney J, Southgate J. Tissue engineering of the urinary bladder: considering structure-function relationships and the role of mechanotransduction. Tissue Eng. 2006;12(4):635-644.
372. Cortivo R, Pagano F, Passerini G, Abatangelo G, Castellani I. Elastin and collagen in the normal and obstructed urinary bladder. Br J Urol. 1981;53(2):134-137.
373. Lemack GE, Szabo Z, Urban Z, Boyd CD, Csiszar K, Vaughan ED, et al. Altered bladder function in transgenic mice expressing rat elastin. Neurourol Urodyn. 1999;18(1):55-68.
374. Hinek A, Smith AC, Cutiongco EM, Callahan JW, Gripp KW, Weksberg R. Decreased elastin deposition and high proliferation of fibroblasts from Costello syndrome are related to functional deficiency in the 67-kD elastin-binding protein. Am J Hum Genet. 2000;66(3):859-872.
375. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease- dermatan sulfate accumulation linked to deficiency in elastinbinding protein and elastic fiber assembly. Am J Pathol. 2000;156(3):925-938.
376. Sutherland RS, Baskin LS, Elfman F, Hayward SW, Cunha GR. The role of type IV collagenases in rat bladder development and obstruction. Pediatr Res. 1997;41(3):430-434.
377. Aitken KJ, Block G, Lorenzo A, Herz D, Sabha N, Dessouki O, et al. Mechanotransduction of extracellular signal-regulated kinases 1 and 2 mitogen-activated protein kinase activity in smooth muscle is dependent on the extracellular matrix and regulated by matrix metalloproteinases. Am J Pathol. 2006;169 (2):459-470.
378. Pattison MA, Wurster S, Webster TJ, Haberstroh KM. Threedimensional, nano-structured PLGA scaffolds for bladder tissue replacement applications. Biomaterials. 2005;26 (15):2491-2500.
379. Nagatomi J, DeMiguel F, Torimoto K, Chancellor MB, Getzenberg RH, Sacks MS. Early molecular-level changes in rat bladder wall tissue following spinal cord injury. Biochem Biophys Res Commun. 2005;334(4):1159-1164.
380. Parekh A, Long RA, Chancellor MB, Sacks MS. Assessing the effects of transforming growth factor-β1 on bladder smooth muscle cell phenotype. II. Modulation of collagen organization. J Urol. 2009;182(3):1216-1221.
381. Parekh A, Long RA, Iannone EC, Chancellor MB, Sacks MS. Assessing the effects of transforming growth factor-β1 on bladder smooth muscle cell phenotype. I. Modulation of in vitro contractility. J Urol. 2009;182(3):1210-1215.
382. Heise RL, Ivanova J, Parekh A, Sacks MS. Generating elastinrich small intestinal submucosa-based smooth muscle constructs utilizing exogenous growth factors and cyclic mechanical stimulation. Tissue Eng Part A. 2009;15(12):3951-3960.
383. Carreras I, Rich CB, Panchenko MP, Foster JA. Basic fibroblast growth factor decreases elastin gene transcription in aortic smooth muscle cells. J Cell Biochem. 2002;85(3):592-600.
384. Erdoǧar N, Iskit AB, Mungan NA, Bilensoy E. Prolonged retention and in vivo evaluation of cationic nanoparticles loaded with Mitomycin C designed for intravesical chemotherapy of bladder tumours. J Microencapsul. 2012. doi:10.3109/02652048.2012.668957.
385. Lu Z, Yeh TK, Tsai M, Au JLS, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res. 2004;10(22):7677-7684.
386. Bilensoy E, Sarisozen C, Esendaǧli G, Doǧan AL, Aktaş Y, Şen M, et al. Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors. Int J Pharm. 2009;371(1-2):170-176.
387. Roth CC, Mondalek FG, Kibar Y, Ashley RA, Bell CH, Califano JA, et al. Bladder regeneration in a canine model using hyaluronic acid-poly(lactic-co-glycolic-acid) nanoparticle modified porcine small intestinal submucosa. BJU Int. 2011;108(1):148-155.
388. Mondalek FG, Lawrence BJ, Kropp BP, Grady BP, Fung KM, Madihally SV, et al. The incorporation of poly (lactic-co-glycolic) acid nanoparticles into porcine small intestinal submucosa biomaterials. Biomaterials. 2008;29(9):1159-1166.
389. Roth CC. Urologic tissue engineering in pediatrics: from nanostructures to bladders. Pediatr Res. 2010;67(5):509-513.
390. Mecham RP, Levy BD, Morris SL, Madaras JG, Wrenn DS. Increased cyclic GMP levels lead to a stimulation of elastin production in ligament fibroblasts that is reversed by cyclic AMP. J Biol Chem. 1985;260(6):3255-3258.
391. Mecham RP, Lange G, Madaras J, Starcher B. Elastin synthesis by ligamentum nuchae fibroblasts: effects of culture conditions and extracellular matrix on elastin production. J Cell Biol. 1981;90(2):332-338.
392. Rich CB, Goud HD, Bashir M, Rosenbloom J, Foster JA. Developmental regulation of aortic elastin gene expression involves disruption of an IGF-I sensitive repressor complex. Biochem Biophys Res Commun. 1993;196(3):1316-1322.
393. Brettell LM, McGowan SE. Basic fibroblast growth factor decreases elastin production by neonatal rat lung fibroblasts. Am J Respir Cell Mol Biol. 1994;10(3):306-315.
394. Davis EC, Mecham RP. Intracellular trafficking of tropoelastin. Matrix Biol. 1998;17(4):245-254.
395. Frisch SM, Davidson JM, Werb Z. Blockage of tropoelastin secretion by monensin represses tropoelastin synthesis at a pretranslational level in rat smooth muscle cells. Mol Cell Biol. 1985;5(1):253-258.
396. Cortizo MC, De Mele MFL. Cytotoxicity of copper ions released from metal-variation with the exposure period and concentration gradients. Biol Trace Elem Res. 2004;102 (1-3):129-141.
397. Hayashi A, Suzuki T, Tajima S. Modulations of elastin expression and cell proliferation by retinoids in cultured vascular smooth muscle cells. J Biochem. 1995;117(1):132-136.
398. Tajima S, Hayashi A, Suzuki T. Elastin expression is up-regulated by retinoic acid but not by retinol in chick embryonic skin fibroblasts. J Dermatol Sci. 1997;15(3):166-172.